Αποτελέσματα Αναζήτησης
This Schedule 14D-9C consists of the following document related to the proposed acquisition of Theseus Pharmaceuticals, Inc. (the “Company” or “Theseus”), pursuant to the terms of an Agreement and Plan of Merger, dated as of December 22, 2023 (the “Merger Agreement”), among the Company, Concentra Biosciences, LLC, a Delaware limited ...
• On December 22, 2023, Theseus Pharmaceuticals, Inc. (Nasdaq: THRX) announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC, will acquire Theseus for a price per share of Theseus common stock of (i) a base cash price of $3.90 per share, (ii) an additional cash amount of not
14 Φεβ 2024 · February 14, 2024. New Deliverable Per Contract: $405.00 Cash ($4.05 x 100) Settlement in THRX options will take place through OCC’s cash settlement system. Settlement will be accomplished by payment of the difference between the extended strike amount and the cash deliverable. Acceleration of Expirations.
22 Δεκ 2023 · Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value Right. CAMBRIDGE, Mass., Dec. 22,...
22 Δεκ 2023 · Theseus shareholders holding approximately 59% of Theseus common stock have signed support agreements under which such shareholders agreed to tender their shares in the Offer and support...
22 Δεκ 2023 · Theseus Pharmaceuticals (NASDAQ: THRX) on Friday said it has entered into an agreement whereby Concentra Biosciences will acquire the oncology-focused biotech for between $3.90 and $4.05 in...
22 Δεκ 2023 · Theseus Pharmaceuticals, Inc. today announced it has entered into a definitive merger agreement (the “Merger Agreement”) whereby Concentra Biosciences, LLC (“Concentra”) will acquire Theseus for a price per share of Theseus common stock.
